US2021393577A1PendingUtilityA1

Combinations of cannabinoids and n-acylethanolamines

72
Assignee: SCISPARC LTDPriority: Apr 29, 2015Filed: Aug 27, 2021Published: Dec 23, 2021
Est. expiryApr 29, 2035(~8.8 yrs left)· nominal 20-yr term from priority
Inventors:Ascher ShmulewitzElran HaberEphraim Brener
A61K 36/3482A61K 31/658A61K 2300/00A61P 25/30A61P 25/14A61K 31/164A61K 45/06A61P 25/00A61P 29/00A61K 36/185A61K 31/352
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

Claims

exact text as granted — not AI-modified
1 - 48 . (canceled) 
     
     
         49 . A pharmaceutical composition comprising a therapeutically-effective amount of at least one synthetic cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof. 
     
     
         50 . The pharmaceutical composition of  claim 49 , wherein the molar ratio between the at least one synthetic cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:0.2 to about 1:2000. 
     
     
         51 . The pharmaceutical composition of  claim 49 , wherein the molar ratio between the at least one synthetic cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:0.2 to about 1:5. 
     
     
         52 . The pharmaceutical composition of  claim 49 , wherein the molar ratio between the at least one synthetic cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:0.5 to about 1:2. 
     
     
         53 . The pharmaceutical composition of  claim 49 , wherein the molar ratio between the at least one synthetic cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:15 to about 1:1800. 
     
     
         54 . The pharmaceutical composition of  claim 49 , wherein the molar ratio between the at least one synthetic cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:25 to about 1:450. 
     
     
         55 . The pharmaceutical composition of  claim 49 , wherein the molar ratio between the at least one synthetic cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:50 to about 1:100. 
     
     
         56 . The pharmaceutical composition of  claim 49 , comprising about 200-1800 mg of N-acylethanolamine or salt thereof. 
     
     
         57 . The pharmaceutical composition of  claim 56 , comprising about 250 mg, about 500 mg, about 750 mg, about 1000 mg or about 1500 mg of the N-acylethanolamine or salt thereof. 
     
     
         58 . The pharmaceutical composition of  claim 49 , wherein the N-acylethanolamine is selected from the group consisting of N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), a salt thereof, or any combination thereof. 
     
     
         59 . The pharmaceutical composition of  claim 58 , wherein the N-acylethanolamine is PEA or a salt thereof 
     
     
         60 . The pharmaceutical composition of  claim 59 , wherein the pharmaceutical composition comprises about 0.5-10 mg of the synthetic cannabinoid or salt thereof, and about 200-1800 mg of the PEA or salt thereof. 
     
     
         61 . The pharmaceutical composition of  claim 60 , wherein the pharmaceutical composition comprises about 2.5-10 mg of the synthetic cannabinoid or salt thereof, and about 250-1000 mg of the PEA or salt thereof. 
     
     
         62 . The pharmaceutical composition of  claim 61 , wherein the pharmaceutical composition comprises about 2.5 mg, about 5 mg, about 7.5 mg or about 10 mg the synthetic cannabinoid or salt thereof, and about 250 mg, about 500 mg, about 750 mg or about 1000 mg of the PEA or salt thereof. 
     
     
         63 . The pharmaceutical composition of  claim 49 , wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, sublingual, inhalational, topical, rectal, vaginal, parenteral, intravenous, intramuscular, or subcutaneous administration. 
     
     
         64 . The pharmaceutical composition of  claim 63 , wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, or sublingual administration. 
     
     
         65 . The pharmaceutical composition of  claim 49 , wherein the therapeutic potency of the pharmaceutical composition is increased compared to the same pharmaceutical composition without the N-acylethanolamine. 
     
     
         66 . The pharmaceutical composition of  claim 49 , wherein the required therapeutic dosage of the synthetic cannabinoid in the pharmaceutical composition is decreased compared to the same pharmaceutical composition without the N-acylethanolamine. 
     
     
         67 . The pharmaceutical composition of  claim 49 , wherein at least one of the side-effects of the synthetic cannabinoid is reduced compared to the same pharmaceutical composition without the N-acylethanolamine. 
     
     
         68 . The pharmaceutical composition of  claim 49 , wherein the therapeutic window of the synthetic cannabinoid is extended compared to the same pharmaceutical composition without the N-acylethanolamine. 
     
     
         69 . A pharmaceutical composition comprising a therapeutically-effective amount of at least one synthetic cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof, wherein the molar ratio between the at least one synthetic cannabinoid and the at least one N-acylethanolamine is between about 1:0.2 to about 1:2000. 
     
     
         70 . The pharmaceutical composition of  claim 69 , wherein the N-acylethanolamine is selected from the group consisting of N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), a salt thereof, or any combination thereof. 
     
     
         71 . The pharmaceutical composition of  claim 70 , wherein the N-acylethanolamine is PEA or a salt thereof 
     
     
         72 . The pharmaceutical composition of  claim 71 , wherein the pharmaceutical composition comprises about 200-1800 mg of the PEA or salt thereof. 
     
     
         73 . The pharmaceutical composition of  claim 72 , wherein the pharmaceutical composition comprises about 250-1000 mg of the PEA or salt thereof. 
     
     
         74 . The pharmaceutical composition of  claim 73 , wherein the pharmaceutical composition comprises about 250 mg, about 500 mg, about 750 mg or about 1000 mg of the PEA or salt thereof. 
     
     
         75 . The pharmaceutical composition of  claim 69 , wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, or sublingual administration. 
     
     
         76 . The pharmaceutical composition of  claim 71 , wherein the therapeutic potency of the pharmaceutical composition is increased compared to the same pharmaceutical composition without the PEA.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.